Avida Biomed Inc.

[Not Yet Scheduled]
Avida Biomed, a biotech company founded by veteran entrepreneurs, focuses on technology-based innovation for molecular diagnostics with an emphasis on epigenetics analysis of cfDNA-based liquid biopsy. Avida’s newly launched Point-n-Seq™ kits allow both genetics and epigenetics analysis with unprecedented sensitivity, dramatically shortened assay time, and full automation capacity. It is the first such kit to offer dual genomic and epigenomic analysis without sample splitting. In collaboration with clinical academic institutes, the Point-n-Seq cancer early detection assays have demonstrated remarkable sensitivity and specificity. Ultimately, Avida strives to provide a fully-automated cfDNA NGS platform that will enable global access to the next level of clinical genomics.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
Targeted Methylation Sequencing Kit, Duo (mutation and methylation) sequencing Kit
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
photo
Head of Clinical Research
Avida Biomed Inc.